Aristeia Capital L.L.C. lessened its stake in Tenet Healthcare Corporation (NYSE:THC - Free Report) by 41.4% in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 3,977 shares of the company's stock after selling 2,814 shares during the quarter. Aristeia Capital L.L.C.'s holdings in Tenet Healthcare were worth $535,000 at the end of the most recent reporting period.
A number of other hedge funds have also recently bought and sold shares of THC. Ameriprise Financial Inc. grew its stake in Tenet Healthcare by 30.1% during the 4th quarter. Ameriprise Financial Inc. now owns 437,672 shares of the company's stock valued at $55,244,000 after purchasing an additional 101,355 shares in the last quarter. Colonial Trust Co SC grew its stake in Tenet Healthcare by 85.7% during the 4th quarter. Colonial Trust Co SC now owns 247 shares of the company's stock valued at $31,000 after purchasing an additional 114 shares in the last quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main grew its stake in Tenet Healthcare by 408.7% during the 4th quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 24,235 shares of the company's stock valued at $3,059,000 after purchasing an additional 19,471 shares in the last quarter. Deutsche Bank AG grew its stake in Tenet Healthcare by 99.3% during the 4th quarter. Deutsche Bank AG now owns 76,048 shares of the company's stock valued at $9,600,000 after purchasing an additional 37,890 shares in the last quarter. Finally, Ethic Inc. grew its stake in Tenet Healthcare by 236.3% during the 4th quarter. Ethic Inc. now owns 6,934 shares of the company's stock valued at $875,000 after purchasing an additional 4,872 shares in the last quarter. Institutional investors and hedge funds own 95.44% of the company's stock.
Insider Activity at Tenet Healthcare
In related news, EVP Lisa Y. Foo sold 8,000 shares of the firm's stock in a transaction that occurred on Wednesday, August 20th. The stock was sold at an average price of $179.53, for a total value of $1,436,240.00. Following the sale, the executive vice president owned 20,878 shares of the company's stock, valued at approximately $3,748,227.34. This trade represents a 27.70% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Christopher S. Lynch sold 3,952 shares of the firm's stock in a transaction that occurred on Tuesday, August 19th. The shares were sold at an average price of $176.39, for a total value of $697,093.28. Following the completion of the sale, the director owned 12,358 shares in the company, valued at approximately $2,179,827.62. This represents a 24.23% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 11,960 shares of company stock worth $2,134,801. Company insiders own 0.81% of the company's stock.
Tenet Healthcare Trading Up 2.0%
Shares of NYSE THC opened at $196.40 on Monday. The company has a market cap of $17.35 billion, a price-to-earnings ratio of 12.57, a price-to-earnings-growth ratio of 0.84 and a beta of 1.55. Tenet Healthcare Corporation has a 12-month low of $109.82 and a 12-month high of $196.73. The company has a current ratio of 1.71, a quick ratio of 1.63 and a debt-to-equity ratio of 2.39. The stock's 50 day simple moving average is $171.97 and its 200 day simple moving average is $153.22.
Tenet Healthcare (NYSE:THC - Get Free Report) last announced its quarterly earnings results on Tuesday, July 22nd. The company reported $4.02 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.84 by $1.18. The business had revenue of $5.27 billion for the quarter, compared to the consensus estimate of $5.16 billion. Tenet Healthcare had a return on equity of 24.69% and a net margin of 7.17%.The business's revenue was up 3.2% on a year-over-year basis. During the same quarter last year, the business posted $2.31 EPS. Tenet Healthcare has set its FY 2025 guidance at 15.550-16.210 EPS. Equities research analysts expect that Tenet Healthcare Corporation will post 12.24 EPS for the current year.
Analyst Ratings Changes
A number of equities research analysts have weighed in on the company. Barclays lowered their price objective on Tenet Healthcare from $215.00 to $208.00 and set an "overweight" rating for the company in a research note on Thursday, July 24th. Stephens raised Tenet Healthcare to a "strong-buy" rating in a report on Monday, June 2nd. UBS Group increased their target price on Tenet Healthcare from $230.00 to $238.00 and gave the stock a "buy" rating in a report on Wednesday, July 23rd. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $190.00 target price on shares of Tenet Healthcare in a report on Tuesday, August 26th. Finally, Wolfe Research downgraded Tenet Healthcare from an "outperform" rating to a "peer perform" rating in a report on Monday, July 28th. One analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and four have assigned a Hold rating to the company's stock. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus price target of $192.69.
Read Our Latest Stock Analysis on THC
Tenet Healthcare Profile
(
Free Report)
Tenet Healthcare Corporation operates as a diversified healthcare services company in the United States. The company operates through two segments: Hospital Operations and Services, and Ambulatory Care. Its general hospitals offer acute care services, operating and recovery rooms, radiology and respiratory therapy services, clinical laboratories, and pharmacies.
Read More
Want to see what other hedge funds are holding THC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Tenet Healthcare Corporation (NYSE:THC - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Tenet Healthcare, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tenet Healthcare wasn't on the list.
While Tenet Healthcare currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.